Introduction
The stomach is an important target organ for gene delivery owing to its capabilities for storing, mixing, digesting, and sterilizing foods with gastric acid. People often suffer from stomach disorders such as acute and chronic gastritis, gastric ulcer, and gastric cancer. Especially, gastric cancer is one of the most common malignant tumors worldwide. Mortality due to gastric cancer in Japan was over 50 000 in 2005 according to the Center for Cancer Control and Information Services, National Cancer Center, Japan. Recently, Matsumoto et al. 1 reported that aberrant expression of activation-induced cytidine deaminase gene by infection of Helicobacter pylori is related to gastric carcinogenesis. Gene therapy targeting oncogenes or tumor-suppressor genes is a candidate for a rationalized therapeutic approach. Several studies have investigated gene therapy for treatment of gastric ulcer 2 and gastric cancer. 3 In vivo gene delivery systems can be categorized as viral 4 or nonviral. 5 Although nonviral vectors generally have low transfection effi ciency, they have safety advantages compared with viral vectors. Naked plasmid DNA (pDNA) is the simplest and safest of the nonviral gene delivery systems because it can be used without concerns about toxicity of the gene carrier. Indeed, clinical investigations have been performed using naked pDNA, which encodes hepatocyte growth factor (HGF), for treatment of peripheral arterial disease in Japan. 6 When we use a gene encoding growth factors, gene expression in nontarget tissues can cause unexpected adverse effects. For example, it has been reported that, although vascular endothelial growth factor (VEGF) plays a role in the ulcer healing process, 7 VEGF is also an important factor in tumors and pathological retinal angiogenesis. 8 Therefore, target-selective or -specifi c gene transfer is desirable for maximal therapeutic action and minimal adverse effects in the clinical use of gene therapy. When foreign genes are administered via the vasculature route, they are distributed to the whole body via the bloodstream, leading to inadequate organselective or disease site-selective gene delivery, and they are rapidly degraded by reticuloendothelial cells (e.g., liver Kupffer cells) and nuclease in the blood. 9 Organ-selective gene transfer using naked pDNA has been achieved by methods such as direct injection, 10 electroporation, 11 and the use of a gene gun. 12 Gene expression in the stomach has been observed in rats after direct injection of pDNA into the gastric submucosa. 13 However, there is great concern about the safety of these procedures because they require physical force against organs; consequently, they are unsuitable for continuous or repetitive administration of pDNA. However, although pDNA complexes with chitosan, 14 N-acetylated chitosan 15 and montmorillonite 16 were studied for oral gene delivery, transfection efficiency could be reduced by factors such as gastric contents, low pH, a high concentration of digestive fl uid, and rapid turnover of epithelial cells. In fact, transgene expression was not observed in the stomach following nanoparticles-in-microsphere oral administration in rats. 17 We previously developed a method for applying drugs onto the surface of intraperitoneal organs such as the liver, 18 kidney, 19 and stomach, [20] [21] [22] and found it to be useful for site-selective drug delivery to these organs. Furthermore, we reported site-selective gene expression following instillation of naked pDNA onto the liver surface, 23 kidney surface, 24 and gastric serosal surface 25 in mice. However, we have not yet confi rmed that foreign gene transfer by organ surface administration can be achieved in animals other than mice. As the rat stomach is bigger than that of mice, target selectivity may be better because the target organ is large in relation to the instillation volume of the pDNA solution; thus, the pDNA solution might not easily diffuse from the target organ to peripheral tissues. Therefore, we hypothesize that a lower volume of pDNA solution would not easily diffuse to nontarget organs and we might thus be able to achieve highly stomach-selective gene expression. Both target size and solution volume may be key factors in target organ-selective gene transfer. To test this hypothesis in the present study, we performed instillation of naked pDNA onto the gastric serosal surface in rats.
Materials and methods

Materials
Sodium pentobarbital was obtained from Abbott Laboratories (Abbott Park, IL, USA). All chemicals used were of the highest purity available.
Animals
Male Wistar rats were purchased from Kyudo (Kumamoto, Japan). They were housed in a cage in an air-conditioned room and maintained on a standard laboratory diet (MF, Oriental Yeast, Tokyo, Japan) and water ad libitum. All animal experiments were carried out in accordance with the Principles of Laboratory Animal Care as adopted and promulgated by the U.S. National Institutes of Health and the Guidelines for Animal Experimentation of Nagasaki University.
Construction and preparation of pDNA
pCMV-luciferase was constructed by subcloning the Hind III/Xba I fi refl y luciferase cDNA fragment from a pGL3-control vector (Promega, Madison, WI, USA) into the polylinker of a pcDNA3 vector (Invitrogen, Carlsbad, CA, USA). In this study, pCMV-luciferase was mainly used, except in the immunohistochemistry experiment. pZsGreen1-N1 encoding reef coral fl uorescent protein was obtained from Takara Bio (Shiga, Japan). Naked pDNA was amplifi ed in Escherichia coli strain DH5α, isolated, and purifi ed using an EndoFree Plasmid Giga Kit (Qiagen, Hilden, Germany). Naked pDNA dissolved in 5% glucose solution was stored at −20°C before the experiments.
Gastric serosal surface instillation
Five-week-old male Wistar rats (140-170 g) were anesthetized with sodium pentobarbital (40-60 mg/kg, intraperitoneal administration). The stomach was exposed by a laparotomy, and naked pDNA solution was quickly instilled onto the gastric serosal surface using a micropipette (Pipetman, Gilson, Villiers-le-Bel, France). The area of instillation was the middle body of stomach. Rats were kept lying on their back for 1 h, and then the abdominal wall and the skin were sutured. Subsequently rats were freed in the cage. At appropriate time intervals (3, 6, 12, 24 , and 48 h) after administration of naked pDNA, a blood sample was taken from the inferior vena cava with a syringe [19 G × 1.5 inch (38 mm) needle, Terumo, Tokyo, Japan]. Immediately after blood sampling, the rats were killed under anesthesia, and the stomach, liver, kidneys (left and right), spleen, diaphragm, heart, and lung were removed with surgical scissors. The tissues were washed twice with saline and homogenized with lysis buffer (4 μl/mg of tissue) consisting of 0.1 M Tris/HCl buffer (pH 7.8) containing 0.05% Triton X-100 and 2 mM EDTA. 26 Blood samples and homogenates were centrifuged at 15 000 g for 5 min. Each supernatant was assayed for luciferase activity.
Intraperitoneal, intragastric, and intravenous administration
Five micrograms (100 μl) of naked pDNA was administered intragastrically, intraperitoneally, and intravenously to anesthetized rats as control experiments. In the intraperitoneal administration study, rats were intraperitoneally administered naked pDNA, kept lying on their back for 1 h, and then freed in the cage. In the intragastric administration study, rats underwent laparotomy and the stomach was exposed. Subsequently, a 26 G × 0.5 inch (13 mm) needle (Nipro, Osaka, Japan) was inserted via the duodenum and pDNA was injected into the stomach. Then, the pinhole was sealed with a thin fi lm of surgical adhesive (Aron Alpha, Sankyo, Tokyo, Japan) and the abdominal wall and skin were sutured. Subsequently, rats were freed in the cage. In the intravenous administration study, rats were administered pDNA via the femoral vein and freed in the cage. The subsequent procedures were the same as for gastric serosal surface instillation experiments.
Luciferase assay
Twenty microliters of tissue homogenate supernatant and plasma were mixed with 100 μl of luciferase assay substrates (PicaGene, Toyo Ink, Tokyo, Japan), and the light produced was immediately measured using a luminometer (MiniLumat LB9506, Berthold Technologies, Bad Wildbad, Germany). The luciferase activity is indicated as relative light units (RLU) per gram of tissue.
Immunohistochemistry
Twenty-four hours after gastric serosal surface instillation of pZsGreen1-N1 (5 μg/5 μl), rats were killed under anesthesia and the stomach was removed. Imprints of the gastric serosal surface cells were prepared by the modifi ed method of Foley-Comer et al. 27 Briefl y, the stomach was washed twice with saline and dried for 5 min at room temperature. Imprints of the gastric serosal surface cells were obtained on MAS-coated glass microscope slides (SUPERFROST S-9441, Matsunami Glass, Osaka, Japan). Imprints were fi xed in 4% paraformaldehyde for 10 min and permeabilized for 5 min with phosphate-buffered saline containing 0.2% Triton X-100. Nonspecifi c staining was reduced with Image-iT FX signal enhancer (Invitrogen) before incubating the imprints with rat monoclonal antibodies (dilution 1 : 50; Santa Cruz Biotechnology, Santa Cruz, CA, USA) directed against zonula occludens-1 (ZO-1) for 1 h at room temperature in a humidifi ed chamber. Then, imprints were incubated with goat anti-rat IgGTexas red as the secondary antibody (dilution 1 : 100; Santa Cruz Biotechnology) for 1 h at room temperature in a humidifi ed chamber. SlowFade Gold antifade reagent (Invitrogen) was applied to the imprints before they were mounted.
Microscopy and imaging
Imprints were analyzed by confocal laser scanning microscopy (LSM 510 META, Carl Zeiss Microimaging, Thornwood, NY, USA).
Statistical analysis
Differences between experimental groups were evaluated statistically using the Steel-Dwass multiple comparison test.
Results
Usefulness of the gastric serosal surface instillation method
We previously demonstrated that the administration of naked pDNA onto the gastric serosal surface in mice resulted in stomach-selective gene expression. 25 In this study, we initially confi rmed whether the instillation of naked pDNA (5 μg/5 μl) onto the gastric serosal surface in rats showed detectable gene expression in the stomach. As controls, we administered 5 μg/100 μl of naked pDNA intragastrically, intraperitoneally, and intravenously. Six hours later, luciferase activity in the stomach was determined. Each tissue homogenate without the administration of naked pDNA was mixed with a luciferase assay substrate and showed 10 3 -10 4 RLU/g tissue, which was background luminescence. Therefore, 10 4 RLU/g tissue was considered to be the detection limit of gene expression in this study. The gene expression level in the stomach after gastric serosal surface instillation was signifi cantly higher than that with the other administration methods (Fig. 1) . Moreover, gene expression was not detected in the liver, kidneys, spleen, diaphragm, heart, lung, or plasma following intraperitoneal, intragastric, or intravenous administration of pDNA (data not shown). These results are consistent with the results in mice.
23,25
Effect of pDNA instillation doses on stomach-selective gene expression
We examined the tissue distribution of gene expression 6 h after gastric serosal surface instillation of several different doses of pDNA in a volume of 5 μl (Fig. 2) . Although gene expression was not detected in the stomach or other tissues with the dose of 1 μg/5 μl (data not shown), gene expression was evident in the stomach Fig. 1 . Gene expression in the stomach 6 h after gastric serosal surface instillation and intraperitoneal (i.p.), intragastric (i.g.), or intravenous (i.v.) administration of pDNA at a dose of 5 μg in rats. Each bar represents the mean + S.E. of at least seven experiments. **P < 0.01, compared with other methods of administration Fig. 2 . Gene expression in the stomach, liver, kidneys (left and right), spleen, diaphragm, heart, lung, and plasma 6 h after gastric serosal surface instillation of pDNA at doses of 2-10 μg (5 μl) in rats. Each bar represents the mean + SE of at least 13 experiments Fig. 3 . Effect of instillation doses on gene expression in the stomach 6 h after gastric serosal surface instillation of pDNA at a volume of 5 μl in rats. Each value represents the mean ± SE of at least 13 experiments. **P < 0.01, compared with the 1-μg group with doses of 2-10 μg. Furthermore, the gene expression level was negligible in the liver, kidneys, spleen, diaphragm, heart, lung, and plasma following gastric serosal surface instillation of naked pDNA. Regardless of the pDNA dose (2-10 μg), highly stomach-selective gene transfer was confi rmed. However, gene expression in the stomach was saturated at doses of more than 5 μg (Fig. 3) .
Effect of instillation volume on stomach-selective gene expression
We examined the tissue distribution of gene expression 6 h after gastric serosal surface instillation of 5 μg of pDNA in several different volumes of solution (Fig. 4) . Gene expression was evident in the stomach for 1-50 μl of pDNA solution, but was negligible in other tissues for 5-50 μl of pDNA solution. When 1 μl of solution was used, gene expression was also detected in the liver and spleen, albeit only slightly. On the other hand, luciferase activities in the stomach tended to gradually decrease for instillation volumes of pDNA solution of up to 10 μl (Fig. 5) .
Time course of gene expression after gastric serosal surface instillation of pDNA
The time course of gene expression after gastric serosal surface instillation of pDNA (5 μg/5 μl) was examined (Fig. 6 ). Gene expression in the stomach was observed and right) , spleen, diaphragm, heart, lung, and plasma 6 h after gastric serosal surface instillation of pDNA at a dose of 5 μg (1-50 μl) in rats. Each bar represents the mean + SE of at least 14 experiments 3 h after instillation of pDNA and increased until 12 h. It peaked between 12 and 24 h after instillation, and decreased to a level similar to 3 h at 48 h. Although gene expression in the spleen was also observed 12 and 24 h after instillation of pDNA, the gene expression level was higher in the stomach during that time interval.
Microscopy of the gastric serosal surface cells
To identify the gene-expressing gastric serosal surface cells, ZO-1 protein, a tight junction-associated protein, was stained after gastric serosal surface instillation of pDNA (pZsGreen1-N1) (Fig. 7) . Gastric serosal surface cells expressing ZsGreen1-N1 protein were surrounded by ZO-1 protein, suggesting that these cells were not macrophages. Since ZO-1 is a tight junction-associated protein, they might be mesothelial cells.
Discussion
Early-stage gastric ulcer and gastric cancer occasionally respond to conventional pharmacological treatment. Also, early-stage gastric cancer can be treated by endoscopic or surgical excision in some cases. However, recurrent and refractory gastric ulcer and advanced gastric cancer generally do not respond to conventional therapy. Thus, stomach-targeted gene transfer is an important method of treatment for these refractory gastric diseases. Gene therapy is a rational approach to these severe diseases because a protein defect or deficiency is frequently involved. In most cases, a viral vector has been used as the gene delivery method to the stomach, but selectivity and safety concerns have been raised about viral vectors. To overcome these problems, researchers have studied the use of an adenoviral vector with a β-catenin/T-cell factor-responsive promoter, which is an activated pathway in gastric cancer cells. 28 However, immunogenicity of adenoviruses restricts safety and effi cacy with repeated administration. Moreover, naked pDNA has advantages in terms of ease of use and productivity. Thus, we developed gastric serosal surface instillation of pDNA as a novel, safe, and stomach-selective gene delivery method.
The present study was performed to confi rm whether stomach-selective gene transfer could be achieved in rats by instillation of naked pDNA onto the gastric serosal surface. We have already reported stomachselective gene transfer by this administration method in mice. 25 However, in that report, gene expression was observed not only in the stomach but also in peripheral tissues, such as the liver, left kidney, and spleen. We instilled 30 μl of pDNA solution onto the mouse stomach, but that volume may be too large for a mouse, causing the pDNA solution to diffuse to peripheral tissues after administration onto the gastric serosal surface. Since rats are bigger than mice, the pDNA solution would be less likely to diffuse to peripheral tissues following gastric serosal surface instillation. Additionally, we decreased the volume of pDNA solution relative to body weight from 1 μl/g for mouse to 0.033 μl/g for rat.
Moreover, in view of the animal scale-up, it is important to obtain data in animals other than mice. In the future, information about the kinetics and distribution of pDNA and transgene products may also be required. It is easier to obtain a large enough volume of biological samples such as blood, bile, urine, and feces from rats than mice. Thus, considering the necessity of such further studies, the present study is a basic and important step in the development of gastric serosal surface instillation as a novel stomach-selective gene transfer method. We compared the gene expression level in the rat stomach 6 h after gastric serosal surface instillation and intraperitoneal, intragastric, or intravenous administration. Gastric serosal surface instillation of pDNA showed evident gene expression in the stomach, while intraperitoneal, intragastric, and intravenous administration resulted in no detectable gene expression there (Fig. 1) . In the intraperitoneal administration, pDNA was mainly instilled onto the small intestine and did not suffi ciently contact the stomach. In the intragastric and intravenous administration, naked pDNA was probably degraded by digestive fl uid in the stomach or by reticuloendothelial cells and nuclease in the blood, respectively. These results suggested that the gastric serosal surface is a candidate novel gene transfer route.
The tissue distribution of gene expression 6 h after gastric serosal surface instillation of pDNA at 2-10 μg (5 μl) was examined (Fig. 2) . Although gene expression in the stomach could be detected with a dose of as little as 2 μg, other tissues showed little or no luciferase activities with doses of 2-10 μg. Since 5 μl is a very small volume in relation to the rat stomach, diffusion of pDNA solution to and its contact with peripheral tissues is likely to be limited. To evaluate the effect of instillation dose on transfection effi ciency, we constructed a curve showing the relationship between pDNA dose and luciferase activity in the stomach (Fig. 3) . The gene expression level was not proportional to the pDNA dose, and luciferase activity peaked at 5 μg. pDNA above a certain amount thus might not be taken up or some of the subsequent processes leading to gene expression might be saturated after uptake of pDNA.
The tissue distribution of gene expression 6 h after gastric serosal surface instillation of pDNA at the dose of 5 μg in 1-50 μl of pDNA solution was examined (Fig.  4) . It is possible that, as the volume of pDNA solution increases, gene expression in non-target tissues would be observed. On the other hand, although a large volume of solution diffuses easily to peripheral tissues after gastric serosal surface instillation, the pDNA concentration is diluted, so, despite the increasing volume of pDNA solution, gene expression might be negligible in peripheral tissues for volumes above 5 μl. To evaluate the effect of the instillation volume of pDNA solution on gene expression, we examined the relationship between pDNA solution volume and luciferase activity in the stomach (Fig. 5) . At volumes up to 10 μl of instilled pDNA solution, the gene expression level in the stomach gradually decreased, but further increases in instillation volume (50 μl) resulted in the maintenance of the same gene expression level in the stomach as that at 10 μl.
The results of time course experiments suggested that gene expression was transient after gastric serosal surface instillation of pDNA and that the stomach selectivity of gene expression was high from 3 to 48 h after instillation (Fig. 6) . Although the pDNA dose to body weight ratio in rats was lower than that in mice, the effective period of gene expression after gastric serosal surface instillation of pDNA in rats was almost the same as that in mice. 25 In our previous studies, we found in situ gene expression following the administration of pDNA in a cylindrical diffusion cell attached to the organ surface only in the targeted tissues. 24, 25 Those reports suggest that diffusion of pDNA to peripheral tissues resulted in gene expression in nonadministered tissues. Contact of pDNA with nontarget tissues is an important factor in target-specifi c gene transfer. For clinical use, however, a diffusion cell may be troublesome and impractical for repeated administration in terms of ease of use and biocompatibility. Here, we demonstrated that highly stomach-selective gene transfer could be achieved by gastric serosal surface instillation of pDNA in rats. Recently, medical instruments, such as endoscopes and laparoscopes have been developed, so a laparotomy would not always be necessary for gastric serosal surface instillation. Indeed, we have already reported that liverand lobe-selective gene transfer can be achieved by instillation of pDNA onto the liver surface in mice with a catheter. 29 Although we evaluated the stomach selectivity of gene expression in the present study, the spatial distribution of pDNA and gene expression after gastric serosal surface instillation is important information for future clinical use. Taking the molecular size of pDNA into consideration, pDNA may hardly penetrate to the mucosal side of the stomach. To check this point, we are considering further study of the spatial distribution using fl uorescent-labeled pDNA, pDNA encoding β-galactosidase or a fl uorescent protein.
Stomach-selective or -specifi c gene transfection methods are expected to be safe and effective treatments against refractory gastric ulcer and gastric cancer. Gastric ulcer and gastric cancer begin on the gastric mucosal side and then invade the gastric serosal side. Gastric serosal surface instillation of pDNA encoding therapeutic genes should increase resistance primarily against the invasion of gastric ulcer or gastric cancer to the serosal side. The ulcer healing process comprises many steps: cell migration, proliferation, reepithelialization, angiogenesis, and matrix deposition. 7 This process involves many genes encoding growth factors, including epidermal growth factor, VEGF, keratinocyte growth factor, HGF, platelet-derived growth factor, basic fi broblast growth factor, and angiopoietins. Genes encoding these growth factors have been reported to have an ulcer healing effect in vivo. 2, [30] [31] [32] Moreover, gene therapy for gastric cancer in vitro and in vivo has been attempted with various strategies, such as transfer of suicide genes, 33 the p51A gene, 34 dominant-negative insulin-like growth factor I receptor gene, 35 and RhoA and RhoC short interfering RNA. 36 Effi cient and targetselective gene delivery systems are important for determining whether gene therapy is successful. Gastric serosal surface instillation of viral or nonviral vectors, as well as of naked pDNA, could potentially successfully achieve stomach-selective gene transfer. In summary, we demonstrated highly stomachselective gene transfer following gastric serosal surface instillation of naked pDNA in rats. However, it is necessary to improve the gene transfection effi ciency for clinical application. Additional studies are also needed to elucidate the mechanism of gene transfer after gastric serosal surface administration of naked pDNA.
